Editorial: Drug development for respiratory infectious diseases and related complications in other systems

2026-03-04

Xueping Yu *

Yu Wang

A Oliva

Mingshan Xue

DOI：10.3389/fmed.2026.1800928

Original

Original request for help

Save

Abstract

En 中文

Translation starts with two deceptively simple questions: do candidate antivirals improve meaningful outcomes in practice; and can mechanistic screening be disciplined enough to yield a short list of testable leads. Chen J. et al. compare oral azvudine with nirmatrelvir/ritonavir in hospitalized COVID-19 patients and report broadly comparable effectiveness and safety in routine care. Importantly; their results read as a reminder that antiviral choice is often determined by context-drug-drug interactions; contraindications; availability; and the timing of presentation within an evolving inpatient pathway-rather than by the assumption of a single universally "best" option. Liu L. et al. approach the same translation challenge from the opposite direction. By integrating in silico screening with bioactivity validation; they identify candidate anti-SARS-CoV-2 and anti-inflammatory constituents within Qingyan Dropping Pills; showing a practical way to triage multi-component therapies without treating them as a black box. Together; these papers sketch a workable "two-lane road": comparative effectiveness to test clinical utility on one side; and mechanism-to-candidate selection on the other. This perspective becomes even more consequential when pneumonia is atypical or severe-settings where the right drug is only available once the right diagnosis is made.Atypical and zoonotic pneumonias can deteriorate quickly; and diagnostic delay can erase the benefit of any antimicrobial. Nie C. et al. illustrate this challenge in a case report of severe Q fever pneumonia presenting during an influenza epidemic. Their report highlights how syndromic overlap can obscure a treatable etiology; and how molecular confirmationparticularly sequencing-can reopen the door to targeted therapy. Seen through a development lens; the message is clear: diagnostics are not ancillary to anti-infective evaluation; they define eligibility and the therapeutic window.Feng B.B. et al. extend this real-world framing to the ICU; describing severe Chlamydia psittaci pneumonia requiring invasive mechanical ventilation and summarizing experience with fluoroquinolone-based management. While prospective comparisons will be needed to refine regimen ranking; well-characterized ICU cohorts help clarify timing; safety signals; and endpoints that future trials can build on. From here; the Topic moves to pediatrics-where the translation gap is often less about identifying an active intervention and more about delivering it reliably and equitably.In children; supportive regimens and prevention strategies can have outsized downstream impact; but only if they are practical and scalable. Zeng L. et al. synthesize a large trial landscape to compare nebulized adjunct drugs added to azithromycin for non-severe pediatric Mycoplasma pneumoniae pneumonia via a network meta-analysis. By ranking commonly used inhaled add-ons; they push adjunctive care away from habit toward evidence-graded selection; while also revealing where heterogeneity in outcomes and protocols limits certainty-an actionable signal for standardization in future pediatric studies. At the prevention end of the continuum; Date J. et al. provide an implementation framework for planning an RSV immunization program for infants using a long-acting monoclonal antibody. Their emphasis on delivery details-stakeholder coordination; logistics; surveillance; and equity-highlights a recurring lesson in respiratory infection control: population impact depends as much on implementation as on pharmacology. Taken together; these pediatric contributions bridge naturally to the Topic's final theme: how comorbidity and immune vulnerability outside the lung reshape both therapeutic choice and outcome.Respiratory infections often unfold in patients for whom guideline algorithms are least reliable; and in whom adverse effects can be as dangerous as the infection itself. Chen X. et al. review myasthenia gravis complicated by community-acquired pneumonia and lay out the high-stakes trade-offs clinicians face: some antimicrobials and supportive agents may worsen neuromuscular transmission; while changes in immunosuppression can trigger disease flare or leave infection uncontrolled. By making these competing risks explicit; the review offers a practical decision structure that can reduce avoidable harm in routine care. Beyond neuromuscular disease; immunosuppression and tissue injury after cancer therapy can create a different set of vulnerabilities. Tian C. et al. report Streptococcus dysgalactiae subsp. dysgalactiae bloodstream infection in breast cancer patients after radiotherapy and chemotherapy; underscoring that progression is sometimes driven not by pulmonary pathology alone but by invasive bacterial disease. Their paper points to a frequently overlooked development priority: drug strategy should be paired with surveillance and rapid diagnostics that enable timely escalation before systemic deterioration. Finally; prevention remains central in chronic airway disease. Shuai T. et al. evaluate non-typeable Haemophilus influenzae and Moraxella catarrhalis vaccine strategies in COPD through a systematic review and meta-analysis. Even when candidate vaccines show acceptable safety; demonstrating consistent reductions in exacerbations and hard outcomes is challenging-yet essential in the face of resistance pressures and the cumulative burden of recurrent infection. By clarifying where evidence is strongest and where gaps remain; their work helps define more rigorous next-step trial designs (population selection; endpoints; immunologic correlates; and regimen standardization).Across these nine papers; the take-home is less a table of contents than a development pathway. Progress is most likely when diagnostics and stratification are embedded into evaluationparticularly for atypical pathogens-so that therapies are tested in the patients and time windows where benefit is plausible. Comparative effectiveness studies remain essential to confirm whether efficacy translates into routine care once access; contraindications; and workflow constraints are accounted for. Implementation planning should be treated as part of the intervention; especially for prevention tools that only deliver impact when coverage is achieved.Perhaps most importantly; the Topic reminds us that "respiratory infection" is often a systems problem: neuromuscular disease; cancer therapy; and chronic lung disease can change both susceptibility and tolerability; shifting the net benefit of any given strategy. Future work that combines structured diagnostics; standardized endpoints; and deliberate focus on high-risk subgroups will be best positioned to narrow the translation gap and improve outcomes across the full continuum of care.

Keywords:

drug development

real-world evidence

antiviral therapy

respiratory infectious diseases

atypical pneumonia

RSV immunization

Editorial: Drug development for respiratory infectious diseases and related complications in other systems

Abstract

Journal

Organization